Buprenorphine/naloxone versus methadone in opioid dependence: A longitudinal survey

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 8, 2011, Pages 871-874

  Curcio, Fabio ^a   Franco, T ^b   Topa, M ^b   Baldassarre, C ^b   Scala, M ^a   Auriemma, F ^a   De Rienzi, S ^a   Stimolo, R ^a   Ferrara, V ^a   Santonicola, A M ^a   Siconolfi, M ^a   De Rosa, G ^a   Del Vecchio, F ^a   Del Tufo, S ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b ASL Napoli 1 Centro   (Italy)

Author keywords

Buprenorphine; Dependence; Methadone; Naloxone; Opioid

Indexed keywords

BUPRENORPHINE; METHADONE; NALOXONE; COCAINE; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; EDUCATIONAL STATUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; OPIATE ADDICTION; SOCIAL STATUS; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; MALE; OPIATE SUBSTITUTION TREATMENT; PSYCHOLOGICAL ASPECT; SOCIAL BEHAVIOR; URINE;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; COCAINE; DRUG THERAPY, COMBINATION; EDUCATIONAL STATUS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHADONE; NALOXONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SOCIAL BEHAVIOR;

EID: 80052384377     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CONNOCK M, JUAREZ-GARCIA A, JOWETT S, FREW E, LIU Z, TAYLOR RJ, FRY-SMITH A, DAY E, LINTZERIS N, ROBERTS T, BURLS A, TAYLOR RS. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171.
2. MEADER N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend 2010; 108: 110-114.
3. FLASSING J. Buprenorphine: a more accessible treatment for opioid dependence. JAAPA 2010; 23: 40-43.
4. GOWING L, ALI R, WHITE JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009; 8: CD002025.
5. BAYER I. The monitoring of trade in and control of psychotropic substances to guard against their diversion. Bull Narc 1983; 35: 3-13.
6. MORATTI E, KASHANPOUR A, LOMBARDELLI T, MAISTO M. Intravenous misuse of buprenorphine. Characteristics and extent among patients undergoing drug maintenance therapy. Clin Drug Investig 2010; 30(Suppl. 1): 3-11.
7. RAFFA RB, PERGOUZZI JV JR. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-1675.
8. AMASS L, LING W, FREESE TE, REIBER C, ANNON JJ, COHEN AJ, MCCARTY D, REID MS, BROWN LS, CLARK C, ZIEDONIS DM, KREJCI J, STINE S, WINHUSEN T, BRIGHAM G, BABCOCK D, MUIR JA, BUCHAN BJ, HORTON T. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13(Suppl. 1): S42-S66.
9. STIMOLO C, FAVERO VD, ZECCHINATO G, BUSON R, CUSIN D, PELLACHIN P, SIMONETTO P. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Clin Drug Investig 2010; 30(Suppl. 1): 27-31.
10. AMATO P. Clinical Experience with Fortnightly Buprenorphine/Naloxone versus Buprenorphine in Italy. Preliminary observational data in an office-based setting. Clin Drug Investig 2010; 30(Suppl. 1): 33-39.